AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17687149 — intervention group
Group type: COMPARATOR
Intervention: Weekly bolus FU plus LV (control)
Number of subjects: 1264
Study 14694457 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 2 mg bid (Ta)
Number of subjects: 480
Study 14694457 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg bid plus PFME (Tp)
Number of subjects: 480
Study 11405384 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg rofecoxib
Number of subjects: 341
Study 11405384 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib
Number of subjects: 341
Study 11405384 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg nabumetone
Number of subjects: 341
Study 11405384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 9990362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin at an initial dose of 1 mg/kg per day
Number of subjects: 58
Study 9990362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 7835207 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control intervention during a 2-week admission
Number of subjects: 34
Study 7835207 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals (control group)
Number of subjects: 34
Study 3189161 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoprene barrier liner
Number of subjects: 8
Study 3189161 — intervention group
Group type: COMPARATOR
Intervention: GORE-TEX barrier liner
Number of subjects: 8
Study 29866383 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 113
Study 29866383 — intervention group
Group type: COMPARATOR
Intervention: Residential Treatment (RT)
Number of subjects: 113
Study 27592119 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic ketosis
Number of subjects: 972
Study 27592119 — intervention group
Group type: COMPARATOR
Intervention: Non-ketotic hyperglycemia
Number of subjects: 972
Study 23670354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg daily for 12 weeks
Number of subjects: 88
Study 23670354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 23361631 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-driven protocol (Smartcare/PS™, Drager Medical)
Number of subjects: 30
Study 23361631 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no protocolized decisions by attending physicians)
Number of subjects: 30
Study 21107585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (nutrition and exercise counseling)
Number of subjects: 61
Study 21107585 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based treatment (GT)
Number of subjects: 61
Study 21107585 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight children (control group)
Number of subjects: 61
Study 19473604 — intervention group
Group type: COMPARATOR
Intervention: Brethmol (4 mg)
Number of subjects: 22
Study 19473604 — intervention group
Group type: COMPARATOR
Intervention: Ventolin (4 mg)
Number of subjects: 22
Study 16499533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal screening for Down syndrome by ultrasound examination (including measurement of fetal nuchal translucency) at 12 to 14 weeks' gestation.
Number of subjects: 24
Study 14982045 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%/Timolol 0.5% combination (COSOPT) eye drops twice daily
Number of subjects: 544
Study 14982045 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% (XALATAN) eye drops once daily
Number of subjects: 544
Study 14982045 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 544
Study 11334097 — intervention group
Group type: EXPERIMENTAL
Intervention: Core warming with the Hotline Fluid Warmer (Sims Level 1, Inc., Rockland, MA)
Number of subjects: 8
Study 11334097 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral warming with the Snuggle Warm Convective Warming System (Sins Level 1, Inc., Rockland, MA)
Number of subjects: 8
Study 9424897 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate repair of biliary tract injuries
Number of subjects: 112
Study 9424897 — intervention group
Group type: COMPARATOR
Intervention: Secondary repair of biliary tract injuries
Number of subjects: 112
Study 9424897 — intervention group
Group type: COMPARATOR
Intervention: Overall surgical treatment
Number of subjects: 112
Study 8176086 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz-Schatz stenting
Number of subjects: 200
Study 2589377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin combined with benzylpenicillin (CB)
Number of subjects: 96
Study 2589377 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin combined with piperacillin (NP)
Number of subjects: 96
Study 1145958 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheie procedure
Number of subjects: 71
Study 1145958 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with a sutured scleral flap
Number of subjects: 71
Study 1145958 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 71
Study 31911179 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera (MO) 400 mg/kg body weight
Number of subjects: 15
Study 31911179 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera hard gelatin capsules
Number of subjects: 15
Study 31456039 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious depression group
Number of subjects: 126
Study 31456039 — intervention group
Group type: COMPARATOR
Intervention: MDD-only group
Number of subjects: 126
Study 31456039 — intervention group
Group type: COMPARATOR
Intervention: Comparison of depressed patients with and without comorbid anxiety disorders
Number of subjects: 126
Study 28805348 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine administered 0 and 30 min before each hemodialysis session
Number of subjects: 33
Study 28805348 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 0 and 30 min before each hemodialysis session
Number of subjects: 33
Study 26537991 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulorhexis diameter of 3.0-3.9 mm (Group A)
Number of subjects: 38
Study 26537991 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulorhexis diameter of 4.0-5.0 mm (Group B)
Number of subjects: 38
Study 26537991 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulorhexis diameter of 5.1-6.0 mm (Group C)
Number of subjects: 38
Study 23601628 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prescription based on physical fitness test results and personal choice
Number of subjects: 72
Study 23601628 — intervention group
Group type: COMPARATOR
Intervention: Nutrition intervention
Number of subjects: 72
Study 21480939 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with oral hygiene instructions (OHI)
Number of subjects: 68
Study 21480939 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions (OHI) alone
Number of subjects: 68
Study 21480939 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 68
Study 21480939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 68
Study 21480939 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (both groups)
Number of subjects: 68
Study 21480939 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP‐8
Number of subjects: 68
Study 19797730 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (DXM) 40 mg/day for four consecutive days
Number of subjects: 17
Study 19797730 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro effects of DXM on peripheral blood mononuclear cells (PBMCs)
Number of subjects: 17
Study 17113554 — intervention group
Group type: COMPARATOR
Intervention: CQ+SP (Homapak)
Number of subjects: 183
Study 17113554 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ+SP
Number of subjects: 183
Study 14760910 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 20
Study 14760910 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroform
Number of subjects: 20
Study 14760910 — intervention group
Group type: COMPARATOR
Intervention: Control (Dentin chips obtained before treatment)
Number of subjects: 20
Study 10793106 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-cisplatin regimen
Number of subjects: 680
Study 10793106 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide-cisplatin regimen
Number of subjects: 680
Study 8803392 — intervention group
Group type: EXPERIMENTAL
Intervention: CEREC (Siemens AG) CAD‐CAM inlay restorations
Number of subjects: 28
Study 1732569 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of 11 mg/kg of amikacin every 12 hours
Number of subjects: 28
Study 1732569 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized pharmacokinetic analysis adjusted amikacin regimens
Number of subjects: 28
Study 6517973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of cigarette smoking
Number of subjects: 107
Study 6517973 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 107
Study 31425751 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step: 2-h, 75 g, oral glucose tolerance test (OGTT)
Number of subjects: 23792
Study 31425751 — intervention group
Group type: COMPARATOR
Intervention: 2-step: 1-h, 50 g glucose challenge test (GCT) followed by 3-h, 100 g OGTT if GCT-positive
Number of subjects: 23792
Study 28737128 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of oseltamivir 75-mg capsule
Number of subjects: 20
Study 28737128 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation Tamiflu®
Number of subjects: 20
Study 27566367 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab monotherapy
Number of subjects: 176
Study 27566367 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with azathioprine (25-100mg daily)
Number of subjects: 176
Study 25332331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric nutritional support (50% of calculated daily caloric requirement of 25-30 kcal · kg(‐1) · d(‐1))
Number of subjects: 83
Study 25332331 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric nutritional support (standard calculated daily caloric requirement of 25-30 kcal · kg(‐1) · d(‐1))
Number of subjects: 83
Study 25332331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric nutritional support
Number of subjects: 83
Study 25332331 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric nutritional support
Number of subjects: 83
Study 21895712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 134
Study 21895712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 19930005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5-10 microg b.i.d.
Number of subjects: 235
Study 19930005 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine o.d.
Number of subjects: 235
Study 19930005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 235
Study 19930005 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 235
Study 17966778 — intervention group
Group type: EXPERIMENTAL
Intervention: New graduated dilator with a standard treatment schedule (20 patients)
Number of subjects: 60
Study 17966778 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple anal dilators (20, 23, 27 mm) with a standard treatment schedule (20 patients)
Number of subjects: 60
Study 17966778 — intervention group
Group type: EXPERIMENTAL
Intervention: New graduated dilator according to a free treatment schedule (20 patients)
Number of subjects: 60
Study 17966778 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated anal dilator according to a free treatment schedule
Number of subjects: 60
Study 15371831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 8000
Study 15371831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8000
Study 11248773 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 61
Study 11248773 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR+CAP pacing
Number of subjects: 61
Study 11248773 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing (less than 50% atrial pacing)
Number of subjects: 61
Study 11248773 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing (less than 90% atrial pacing)
Number of subjects: 61
Study 10350928 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality environment viewed through a head-mounted display
Number of subjects: 0
Study 10350928 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality environment viewed on a two-dimensional computer screen
Number of subjects: 0
Study 10350928 — intervention group
Group type: EXPERIMENTAL
Intervention: Phobic virtual environment exposure
Number of subjects: 0
Study 7989211 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus exercise (group B1)
Number of subjects: 258
Study 7989211 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus exercise plus teaching‐counseling sessions (group B2)
Number of subjects: 258
Study 7989211 — intervention group
Group type: COMPARATOR
Intervention: Usual medical and nursing care (control group A)
Number of subjects: 258
Study 2486557 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 1000
Study 2486557 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass surgery
Number of subjects: 1000
Study 30734085 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg calcium supplement
Number of subjects: 450
Study 30734085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 28109321 — intervention group
Group type: EXPERIMENTAL
Intervention: SW-CRCTs
Number of subjects: 123
Study 25943912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-Track Surgery (FTS-1)
Number of subjects: 256
Study 25943912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-Track Surgery (FTS-2)
Number of subjects: 256
Study 25943912 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care (CC-1)
Number of subjects: 256
Study 25943912 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care (CC-2)
Number of subjects: 256
Study 22580904 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy
Number of subjects: 105
Study 22580904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive bimanual training
Number of subjects: 105
Study 22580904 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 105
Study 22221683 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group (n = 40): 1 mL (10 mg) nalbuphine diluted with 1 mL lidocaine (20 mg)
Number of subjects: 80
Study 22221683 — intervention group
Group type: COMPARATOR
Intervention: Saline group (control) (n = 40): 1 mL (10 mg) nalbuphine diluted with 9 mL normal saline
Number of subjects: 80
Study 19401804 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000U Botulinum toxin type B (BTX-B)
Number of subjects: 36
Study 16557440 — intervention group
Group type: EXPERIMENTAL
Intervention: OTCI
Number of subjects: 50
Study 16557440 — intervention group
Group type: COMPARATOR
Intervention: MCI
Number of subjects: 50
Study 12752837 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention program (staff education, environmental adjustment, exercise, drug review, aids, hip protectors, postfall problem-solving conferences)
Number of subjects: 378
Study 12752837 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 378
Study 11103860 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 84
Study 11103860 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 84
Study 9193126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed treatment with minimal therapist contact (five meetings, readings, self-directed exposure with response prevention)
Number of subjects: 9
Study 9193126 — intervention group
Group type: COMPARATOR
Intervention: Waiting period (6-week delay before treatment)
Number of subjects: 9
Study 1735279 — intervention group
Group type: EXPERIMENTAL
Intervention: bid dosing (4 inhalations bid)
Number of subjects: 16
Study 1735279 — intervention group
Group type: COMPARATOR
Intervention: qid dosing (2 inhalations qid)
Number of subjects: 16
Study 3992162 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 55
Study 3992162 — intervention group
Group type: COMPARATOR
Intervention: Non-restricted diet (Control)
Number of subjects: 55
Study 30519577 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Temperature Plasma Radiofrequency Ablation (LTP-RFA)
Number of subjects: 131
Study 30519577 — intervention group
Group type: COMPARATOR
Intervention: Carbon Dioxide Laser Microsurgery (CO2-LS)
Number of subjects: 131
Study 26381054 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg at steady state
Number of subjects: 26
Study 26381054 — intervention group
Group type: COMPARATOR
Intervention: Combined Oral Contraceptive (OC) alone (reference)
Number of subjects: 26
Study 25200821 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical falloposcopy tubal dilatation (TFTD) after laparoscopic salpingolysis, salpingostomy
Number of subjects: 468
Study 25200821 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic salpingolysis, salpingostomy
Number of subjects: 468
Study 23354115 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (daily subcutaneous injection of 20 μg)
Number of subjects: 62
Study 23354115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate (daily oral administration of 2.5 mg of risedronate)
Number of subjects: 62
Study 23354115 — intervention group
Group type: COMPARATOR
Intervention: Control (without medication for osteoporosis)
Number of subjects: 62
Study 21206545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 10
Study 21206545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17940144 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of both the rotator cuff and type II SLAP lesion (group 1)
Number of subjects: 63
Study 17940144 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of the rotator cuff and tenotomy of the long head of the biceps (group 2)
Number of subjects: 63
Study 17940144 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group 1 and group 2
Number of subjects: 63
Study 16798472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EXE) - prescribed and supervised 4 h/week brisk walking on a treadmill at 50% to 85% of heart rate reserve
Number of subjects: 78
Study 16798472 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 78
Study 16798472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EXE)
Number of subjects: 78
Study 16798472 — intervention group
Group type: EXPERIMENTAL
Intervention: Change on Hallux VPT from baseline to the end of the study
Number of subjects: 78
Study 16798472 — intervention group
Group type: EXPERIMENTAL
Intervention: Change on Malleolus VPT between the two groups
Number of subjects: 78
Study 14713374 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia condition (narrated animation)
Number of subjects: 120
Study 14713374 — intervention group
Group type: COMPARATOR
Intervention: Unimodal condition (visually presented worked examples)
Number of subjects: 120
Study 14713374 — intervention group
Group type: COMPARATOR
Intervention: Conventional condition (solving conventional problems)
Number of subjects: 120
Study 10096378 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of neoadjuvant combined androgen blockade (CAB)
Number of subjects: 40
Study 10096378 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant combined androgen blockade (CAB)
Number of subjects: 40
Study 7674681 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of alcohol
Number of subjects: 40
Study 7674681 — intervention group
Group type: COMPARATOR
Intervention: Active-placebo
Number of subjects: 40
Study 2297598 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory notebook logging
Number of subjects: 6
Study 2297598 — intervention group
Group type: COMPARATOR
Intervention: Written rehearsal
Number of subjects: 6
Study 2297598 — intervention group
Group type: COMPARATOR
Intervention: Verbal rehearsal
Number of subjects: 6
Study 2297598 — intervention group
Group type: COMPARATOR
Intervention: Acronym formation
Number of subjects: 6
Study 7042888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh concentrated Egyptian liquid BCG vaccine (2 mg/ml) given in gradually increasing doses.
Number of subjects: 21
Study 7042888 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients) did not receive any further treatment after chemotherapy.
Number of subjects: 21
Study 30446398 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 5449
Study 30446398 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES) with longer DAPT (>6 months)
Number of subjects: 5449
Study 30446398 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES) with shorter DAPT
Number of subjects: 5449
Study 30446398 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 5449
Study 28771493 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (LNS) 20g daily
Number of subjects: 3436
Study 28771493 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplementation (Z-Suppl)
Number of subjects: 3436
Study 25767103 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-yearly endoscopic surveillance
Number of subjects: 3400
Study 25767103 — intervention group
Group type: COMPARATOR
Intervention: 'At need' endoscopy
Number of subjects: 3400
Study 23829890 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P 260 mg/m(2) q3w with bevacizumab 15 mg/kg q3w
Number of subjects: 208
Study 23829890 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P 260 mg/m(2) q2w with filgrastim and bevacizumab 10 mg/kg q2w
Number of subjects: 208
Study 23829890 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P 130 mg/m(2) weekly with bevacizumab 10 mg/kg q2w
Number of subjects: 208